Study of LKB1-AMPK-mTOR signaling pathway in lung cancer cells
Lung cancer has the highest incidence and top death rates among human neoplasms in china. Clinically, non-small-cell lung cancer (NSCLC) accounts for about 80% -85% of the total number of lung cancer, with an overall 5-year survival rate of about 15%. Understanding the molecular mechanisms underlying NSCLC development may lead to improvement of lung cancer diagnosis and treatment. Tumor suppressor LKB1, also known as STK11, encodes a serine/threonine protein kinase. Germ-line mutations in LKB1 give rise to Peutz-Jeghers syndrome, a disorder characterized by benign hamartomas of the gastrointestinal tract and a predisposition to certain cancers. Somatic mutation analyses indicate that biallelic inactivation of LKB1 is present in 30% of NSCLC primary tumors and cell lines.
非小细胞肺癌 细胞发育 抑制基因 分子机制
Lin-lin Sun Xia Zhang Dian-sheng Zhong Li-xia Dong Zhe Chen Lin-juan Lin
Department of Respiratory Diseases, Tianjin Medical University General Hospital
国内会议
2011中华医学会呼吸病学年会暨第十二次全国呼吸病学学术会议
广州
英文
582-583
2011-09-15（万方平台首次上网日期，不代表论文的发表时间）